MK 886 inhibits leukotriene biosynthesis (IC50 = 2.5 nM) in vitro and tumor activity in vivo. Displays PPARα antagonist activity. Orally active in vivo. MK-886, has been described that blocks the synthesis of leukotrienes in intact activated leukocytes, but has little or no effect on enzymes involved in leukotriene synthesis, including 5-lipoxygenase, in cell-free systems. MK 886 is a potent inhibitor of leukotriene biosynthesis both in vitro and in vivo indicating that the compound is suitable for studying the role of leukotrienes in a variety of pathological situations. MK 886 inhibited A23187-induced LTB4 formation by rat peripheral blood and elicited PMN.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 100 mg/mL
Ethanol 5 mg/mL
Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886.
Kehrer JP, et al. Biochem J. 2001 Jun 15;356(Pt 3):899-906. PMID: 11389700.
L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.
Gillard J, et al. Can J Physiol Pharmacol. 1989 May;67(5):456-64. PMID: 2548691.
Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.
Dixon RA, et al. Nature. 1990 Jan 18;343(6255):282-4. PMID: 2300173.
5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.
Mancini JA, et al. Mol Pharmacol. 1992 Feb;41(2):267-72. PMID: 1538707.
|Related Lipoxygenase Products|
AKBA is an active triterpenoid compound from the extract of Boswellia serrata and Boswellia carteri Birdw, exerts anti-inflammatory therapeutic effects and noncompetitively inhibits 5-lipoxygenase, topoisomerase, and leukocyte elastase.
GSK2190915 (AM803), a potent FLAP inhibitor, prevents the synthesis of leukotrienes and 5-oxo-ETE, with IC50 of 76 nM for inhibition of LTB4 in human blood, provides treatment for asthma.
Zileuton is an orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis with IC50 values of 0.56, 2.3 and 2.6 μM in dog, rat and human blood respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.